These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26546457)

  • 1. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.
    Kus T; Aktas G; Alpak G; Kalender ME; Sevinc A; Kul S; Temizer M; Camci C
    Support Care Cancer; 2016 May; 24(5):2085-2091. PubMed ID: 26546457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
    Durand JP; Deplanque G; Montheil V; Gornet JM; Scotte F; Mir O; Cessot A; Coriat R; Raymond E; Mitry E; Herait P; Yataghene Y; Goldwasser F
    Ann Oncol; 2012 Jan; 23(1):200-205. PubMed ID: 21427067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.
    Zimmerman C; Atherton PJ; Pachman D; Seisler D; Wagner-Johnston N; Dakhil S; Lafky JM; Qin R; Grothey A; Loprinzi CL
    Support Care Cancer; 2016 Mar; 24(3):1071-8. PubMed ID: 26248652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
    Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
    J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early taxane exposure and neurotoxicity in breast cancer patients.
    Cimbro E; Dessì M; Ziranu P; Madeddu C; Atzori F; Lai E; Pretta A; Mariani S; Donisi C; Spanu D; Pozzari M; Murgia S; Saba G; Codipietro C; Palmas E; Sanna G; Semonella F; Sardo S; Finco G; Scartozzi M
    Support Care Cancer; 2024 Oct; 32(10):709. PubMed ID: 39375221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
    Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
    J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
    Schneider BP; Zhao F; Ballinger TJ; Garcia SF; Shen F; Virani S; Cella D; Bales C; Jiang G; Hayes L; Miller N; Srinivasiah J; Stringer-Reasor EM; Chitalia A; Davis AA; Makower DF; Incorvati J; Simon MA; Mitchell EP; DeMichele A; Miller KD; Sparano JA; Wagner LI; Wolff AC
    J Clin Oncol; 2024 Aug; 42(24):2899-2907. PubMed ID: 38828938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of oxaliplatin-induced neuropathy: a patient perspective.
    Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
    Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
    Wu S; Bai X; Guo C; Huang Z; Ouyang H; Huang J; Zeng W
    BMC Cancer; 2021 Nov; 21(1):1173. PubMed ID: 34727879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.
    Durand JP; Brezault C; Goldwasser F
    Anticancer Drugs; 2003 Jul; 14(6):423-5. PubMed ID: 12853883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.
    Durand JP; Alexandre J; Guillevin L; Goldwasser F
    Anticancer Drugs; 2005 Jun; 16(5):587-91. PubMed ID: 15846125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors.
    Zhu Y; Yang J; Jiao S; Ji T
    World J Surg Oncol; 2013 Jan; 11():19. PubMed ID: 23351188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].
    Kowalski T; Maier C; Reinacher-Schick A; Schlegel U
    Schmerz; 2008 Feb; 22(1):16-23. PubMed ID: 17578604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
    Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
    Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
    Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
    Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.